Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 32,80 € (+27 233,33 %). La médiane est de 32,80 € (+27 233,33 %).
| Acheter |
4 |
| Conserver |
1 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
BiomX acquires 10% of M.E.A. Testing Systems and secures option to buy majority
BiomX purchases 324,573 shares (10% diluted) of M.E.A. Testing Systems for $50,000 and 1,300,000 restricted common shares, and receives an exclusive option until June 30, 2028 to acquire the remaining approximately 78.9% at a price of two times net revenue or four times EBITDA for fiscal year 2027. Closing is contingent on approval of an NYSE American listing application and the execution of a license agreement that grants BiomX exclusive worldwide rights to MEA technologies, including drone testing solutions. The transaction takes place despite strained liquidity at BiomX (debt-funded free cash flow of -$23m; financial health score 1.45) and is accompanied by the appointment of Roy Timor-Rousso as chief business officer to strengthen focus on defense and security technologies. » Plus sur de.investing.com
BiomX completes acquisition of AI security software provider Zorronet
BiomX has completed the full takeover of Zorronet from Water.io, expanding its portfolio with AI-driven command-and-control software that links video analytics, drones, sensors and IoT into an operational picture. Zorronet holds contracts with the Israel Defense Forces and Israel Railways and serves customers such as Elbit Systems, addressing defense, security and rescue segments. BiomX has a market capitalization of around USD 20 million and a current ratio of 2.7, but faces challenges from rapid cash burn despite a high gross margin. » Plus sur de.investing.com
BiomX reports quarterly EPS of -21.39 USD and reduces annual loss
BiomX released figures for the quarter ended 31 December 2025 with earnings per share (EPS) of -21.39 USD versus -21.85 USD a year earlier. For the fiscal year the company reported a loss per share of -22.19 USD after -27.93 USD in the prior year. » Plus sur finanzen.net
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 290,9 k | - |
| Bénéfice brut | 84,99 k | 134,31 % |
| Bénéfice net | -3,31 M | 35,47 % |
| EBITDA | -3,34 M | 31,02 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,21 M € |
Nombre d'actions | 10,15 M |
Plus haut/bas sur 52 semaines | 10,61 € - 0,10 € |
| Dividendes | Non |
Bêta | 1,37 |
Ratio P/E | -0,01 |
Ratio PEG | 0,00 |
Ratio P/B | 0,13 |
Ratio P/S | 4,23 |
Profil de l'entreprise
| Nom | BIOMX INC. NEW Aktie |
| PDG | Michael Oster |
| Employés | 20 |
Découvrir des actifs
Les actionnaires de BIOMX INC. NEW Aktie investissent également dans les actifs suivants







